tbuckley/cabot-search huggingface dataset:
Abstract 5759: Intramyocardial Application Of Erythropoietin And Expanded Endothelial Progenitor Cells Improve Regional Left Ventricular Function After Induced Myocardial Infarction In Rats
Authors: Andreas Stein, Antti Saraste, Marcus Makowski, Sandra Kühnel, Elisabeth Weidl, Alex Keithahn, Martina Knoedler, Rene Botnar, Markus Schwaiger, Albert Schomig, Ilka Ott
Journal: Circulation (2008)

Background : Experimental studies showed that application of expanded endothelial progenitor cells (eEPC) after myocardial infarction improves cardiac function by enhancing vasculogenesis and by paracrine effects. Erythropoietin beta (EPO) could further improve myocardial function through its anti-apoptotic properties. Methods : Acute myocardial ischemia was induced by ligation of the left anterior descending coronary artery of 23 male athymic nude rats and reperfusion was initiated after 30 minutes. Either 1×10^6 eEPC alone (n=8), 50 IU erythropoietin beta alone (n=7) or eEPC and EPO (n=8) were injected intramyocardially into the border zone of the ischemic area. eEPC were attained by expanding CD34+ cells isolated from cord blood in endothelial medium for 6 –10 passages. A control group did not receive cells or erythropoietin (n=5). After 4 weeks global and regional left ventricular function was measured by MRI in 2- and 4-chamber long-axis series (Philips Achieva MR Scanner). Immunhistology was used to determine vessel densitiy (SMC actin) and infiltrating monocytes (CD68) after 3 days (n=15) and 4 weeks. Results : Global left ventricular function after 4 weeks was higher in rats that received eEPC alone (58±3%, p=.02) or eEPC + EPO (58±6%, p=.01) compared to the control group (54±5%). No changes were found for rats treated with EPO alone (52±4%). Analysis of the regional wall movement showed a further improvement of the movement of the antero-lateral segments only in rats that obtained eEPC + EPO. The number of CD68+ mononuclear cells after 3 days was highest in rats that were treated with eEPC + EPO. This was associated with an increase in vessel density after 4 weeks. In vitro experiments revealed a dose-dependent inhibition of apoptosis by EPO in eEPC. Conclusion: Intramyocardial transplantation of eEPCs + EPO further improved anterolateral wall motion as compared to EPC alone. Improved eEPC survival, alterations in local inflammatory responses and neovascularization may contribute to this effect.
DL,no; slave to a rhythm?
Authors: Antoinette Houtkooper, P.J.A.M. van Ooij, R.A. van Hulst
Journal: European Respiratory Journal (2011)

Background:  It is generally accepted that spirometry and diffusing capacity are subjected to a diurnal rhythm (CINKOTAI 1966, BORSBOOM 1999, MEDAROV 2008). Values for VC, for example, are lowest around noon and highest between 3.00 and 4.00 pm (MEDAROV 2008,) while DL,co is highest between 08.00 and 09.00 am and decreases during the day (CINKOTAI 1966, MEDAROV 2008).   Introduction:  The aim of this study was to investigate the diurnal rhythm for DL,no. The DL,no is a relatively new method and for applying in studies it is important to know whether there is a diurnal rhythm or not.   Methods:  Eleven male subjects were measured between 8 am and 10 pm. In this period DL,no was measured six times using a Masterscreen PFT-Pro (CareFusion), each time with a pause of at least two hours (max 4 hours).   Statistics:  The Shapiro-Wilk test was used to test for normality. To determine diurnal variance, within-day variations were tested using the one-way Analysis of Variance (Anova). The Bonferroni correction was used to account for multiple comparisons. However, as diurnal variations can be curve shaped we also tested this index with a fractional polynomial regression model.   Results:  The Anova test with Bonferroni correction showed no significant diurnal variation in DL,no (p=0.854). Also the fractional polynomial regression model to the 4th degree or lower did not show any significant relationship between time of the day and DL,no (p=0.526).   Conclusion:  In our study DL,no does not have a diurnal rhythm. We would like to expand our group of subjects to confirm this statement. Further investigation is therefore necessary.
A Quantitative Study of the Effects of X Radiation on Cells &lt;italic&gt;in Vitro&lt;/italic&gt;&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Thomas R. Reid, Margaret P. Gifford
Journal: JNCI Journal of the National Cancer Institute (1952)

A Quantitative Study of the Effects of X Radiation on Cells in Vitro2 Thomas R. Reid, M.D., Thomas R. Reid, M.D. National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret P. Gifford, M.Sc. Margaret P. Gifford, M.Sc. National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar 3Present address: Department of Radiology, U.S. Public Health Service Hospital, Baltimore, Maryland. 4National Institutes of Health, Public Health Service, Federal Security Agency. Author Notes JNCI: Journal of the National Cancer Institute, Volume 13, Issue 2, October 1952, Pages 431–439, https://doi.org/10.1093/jnci/13.2.431 Published: 01 October 1952 Article history Received: 28 May 1952 Published: 01 October 1952
Abstract P023: Relationship Between Vitamin D Status and Incidence of Macro-vascular Events in the Veterans Affairs Diabetes Trial (VADT)
Authors: Jimmy D Alele, Kelly J Hunt, Bruce W Hollis, Deirdre K Luttrell, Louis M Luttrell
Journal: Circulation (2012)

BACKGROUND: Few studies have examined the relationship between vitamin D levels and incident cardiovascular events in large well-characterized type 2 diabetes cohorts. METHODS: We performed prospective analyses to determine associations between vitamin D status and vascular endpoints among 936 Veterans Affairs Diabetes Trial (VADT) participants (mean age 59.7 years; 96.7% male; 40.4% minority). 25 (OH)-vitamin D was measured a median of two years after entry into the VADT study and participants were subsequently followed an average of 3.7 years for outcomes. Cox proportional hazard models were used to calculate hazard ratios (HRs) for macrovascular endpoints in relation to vitamin D quartile. The primary composite endpoint included documented myocardial infarction; stroke; death from cardiovascular causes; new or worsening congestive heart failure; surgical intervention for cardiac, cerebrovascular, or peripheral vascular disease; inoperable coronary artery disease; and amputation for ischemic gangrene. RESULTS: On average VADT participants had high cardiovascular risk at entry into the study: 65.3% of the patients recruited were obese, 38.5% had previously had a vascular event, 78.7% had hypertension and 59.5% were using statins. During follow-up, 17.2%, 5.0%, 5.9%, 2.4% and 6.6% of participants had a primary composite endpoint, myocardial infarction, chronic heart failure, cardiovascular death or all-cause death, respectively. After adjusting for age, minority status, treatment arm and history of prior event, individuals in the lowest quartile of vitamin D (i.e., 1 to 15.9 ng/ml) were at similar risk of the primary composite endpoint [HR=1.26 (95% CI: 0.81, 1.96)], myocardial infarction [HR=1.13 (95% CI: 0.53, 2.42)], congestive heart failure [HR=1.44 (95% CI: 0.67, 3.06)], cardiovascular death [HR=0.86 (95% CI: 0.28, 2.63)], and death from any cause [HR=1.04 (95% CI: 0.53, 2.04)] as individuals in the highest quartile of vitamin D (i.e., 29.9 to 77.2 ng/ml). CONCLUSIONS: These data indicate that vitamin D status had no significant impact on the incidence of macrovascular events in a cohort of high-risk veterans with type 2 diabetes mellitus in which traditional risk factors were managed according to current treatment guidelines. SUPPORT: This work was supported by American Heart Association Grant-in-Aid AHA0755466U and the Research Service of the Charleston SC VA Medical Center.
Multimodality Imaging in Transcatheter Aortic Valve Implantation and Post-Procedural Aortic Regurgitation
Authors: Andrew Jabbour, Tevfik F. Ismail, Neil Moat, Ankur Gulati, Isabelle Roussin, Francisco Alpendurada, Bradley Park, Francois Okoroafor, Anita Asgar, Sarah Barker, Simon Davies, Sanjay K. Prasad, Michael Rubens, Raad H. Mohiaddin
Journal: Journal of the American College of Cardiology (2011)
Abstract 5579: Possible Role of Platelet Reactivity in No-reflow Phenomenon in Patients With Acute Myocardial Infarction
Authors: Cristina Aurigemma, Giancarla Scalone, Lucy Barone, Antonio Di Monaco, Priscilla Lamendola, Alfonso Sestito, Gaetano A Lanza, Filippo Crea
Journal: Circulation (2009)

Background The no-reflow phenomenon has been documented in about 30% of patients with acute myocardial infarction (AMI) undergoing successful recanalization of the infarct-related coronary artery. Several mechanisms have been suggested for no-reflow, including leukocyte and platelet plugging. In this study we investigated whether platelet reactivity and platelet-leukocyte interaction are increased in AMI patients with evidence of no-reflow phenomenon. Methods We studied 14 patients 1 month after AMI (M/F 9/5; age 55±12), and 18 patients with stable coronary artery disease (CAD) (M/F 11/7; age 55±7). AMI patients were divided into two groups: 9 patients with normal coronary flow (group REFLOW) and 5 patients with no-reflow (TIMI flow ≤2 and myocardial blush grade ≤2: group NO-REFLOW). Flow cytometry was used to measure platelet expression of CD41 and glycoprotein IIb/IIIa epitope PAC-1, and monocyte-platelet aggregates (MPA, expressed as percentage of monocytes binding platelets). Results Platelet CD41 were no different between three groups (p=0.84). Instead PAC-1 platelet expression, however, was increased in group NO-REFLOW compared to both group REFLOW (9.7±1.2 mfi vs 6.8±1.6 mfi; p=0.004) and stable CAD patients (6.2±1.4 mfi; p=0.001). Similarly, MPA were increased in group NO-REFLOW compared to both the group REFLOW (20.9±2.4% vs 14.6±3.8%; p=0.012) and stable CAD patients (10.1±1.2%; p&lt;0.0001). Conclusions Platelet reactivity is increased at 1-month follow-up in AMI patients with evidence of no-reflow after successful coronary revascularization. This findings suggest that increased platelet reactivity might be involved in the mechanisms responsible for the no-reflow phenomenon.
High prevalence of intermittent acute porphyria in a psychiatric patient population
Authors: P V Tishler, B Woodward, J O'Connor, D A Holbrook, L J Seidman, M Hallett, D J Knighton
Journal: American Journal of Psychiatry (1985)

The authors screened 3,867 psychiatric inpatients for intermittent acute porphyria by use of a spot test to detect diminished activity of the erythrocyte enzyme porphobilinogen (PBG) deaminase. Eighteen individuals so identified also had persistently diminished quantitative activity of PBG deaminase. Eight of these appeared to have intermittent acute porphyria by the added criteria of increased urinary delta-aminolevulinic acid or PBG or a family history of intermittent acute porphyria. The overall prevalence of intermittent acute porphyria was 0.21%, a considerably higher rate than that in the general population. Most of the subjects with the disorder had periods of agitated psychosis and apathetic or depressed withdrawal, with signs of neuropsychological impairment. Neurologic abnormalities were not prevalent.
Concomitant chemoradiotherapy (CTRT) as induction versus consolidation treatment in patients (pts) with stage III unresectable non-small cell lung cancer (NSCLC): a phase III randomized study by the European Lung Cancer Working Party.
Authors: Marianne Paesmans, Thierry Berghmans, Vicente Giner, Martine Roelandts, Peggy Wackenier, Anne-Pascale Meert, Nathalie Leclercq, Paul Van Houtte, Jean-Paul Sculier
Journal: Journal of Thoracic Oncology (2008)
Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort
Authors: Peter K. Smith, Lawrence T. Goodnough, Jerrold H. Levy, Robert S. Poston, Mary A. Short, Govinda J. Weerakkody, LeRoy A. LeNarz
Journal: Journal of the American College of Cardiology (2012)
多关节肿痛-发热-咳嗽
Authors: 王俏镟, 沈敏
Journal: BMJ (2011)

患者女,35岁,因多关节肿痛2年余,发热伴咳脓痰1年余于2010年12月23日收入北京协和医院.患者于2008年10月感冒后出现左手第1掌指关节(MCP)和右足第1跖趾关节(MTP)肿痛,后逐渐出现双手第3、5近端指间关节(PIP)和双肩、肘关节肿痛,晨起为著,无发热、晨僵.自服布洛芬症状可缓解,停药后加重,于当地医院查红细胞沉降率(ESR)增快,考虑风湿,予雷公藤多苷20mg、3次/d及中药治疗,疼痛可缓解.2009年9月感冒后出现畏寒、发热,最高温度40℃,无寒战,咳少量黄脓痰,伴活动后气短,再次出现关节肿痛,并累及双颞下颌关节.予左氧氟沙星无效。
THE CONTROL OF MASSIVE PULMONARY HEMORRHAGE BY PNEUMOPERITONEUM
Authors: Arthur J. Logie, Harrison A. Walker, Guy R. Stoddard
Journal: Annals of Internal Medicine (1943)

Case Reports1 October 1943THE CONTROL OF MASSIVE PULMONARY HEMORRHAGE BY PNEUMOPERITONEUMARTHUR J. LOGIE, M.D., F.A.C.P., HARRISON A. WALKER, M.D., F.A.C.S., GUY R. STODDARD, M.D.ARTHUR J. LOGIE, M.D., F.A.C.P.Search for more papers by this author, HARRISON A. WALKER, M.D., F.A.C.S.Search for more papers by this author, GUY R. STODDARD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-19-4-685 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptArtificial pneumoperitoneum has become a valuable addition to the armamentarium of the phthisiologist in the treatment of selected cases of pulmonary tuberculosis.1 The safety of inducing and maintaining a pneumoperitoneum, particularly from the pathological aspect, appears well established. Reports of repeated studies on autopsy material stress the fact that there are no changes in the abdominal viscera which can be attributed to the air introduced into the peritoneal space.2Although uncontrollable hemorrhage from the lungs is considered an indication for this type of therapy, there is no mention in the literature of a case treated in this manner. It is...Bibliography1. BANYAI AL: Therapeutic pneumoperitoneum, Am. Rev. Tuberc., 1934, xxix, 603. Google Scholar2. FOWLER WO: Pneumoperitoneum in the treatment of pulmonary tuberculosis, Am. Rev. Tuberc., 1941, xlix, 474-478. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Miami Beach, Florida*Received for publication February 25, 1942. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLOCALIZED PULMONARY DISEASESPneumoperitoneum in the treatment of pulmonary tuberculosis 1 October 1943Volume 19, Issue 4Page: 685-690KeywordsAutopsyHemorrhageLungsSafety ePublished: 1 December 2008 Issue Published: 1 October 1943 PDF downloadLoading ...
Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy
Authors: Shankar Siva, Brent Chesson, Jason W. Callahan, Nicholas Hardcastle, Lisa Crawford, Phillip Antippa, Gavin Wright, Michael P. MacManus, Rodney J. Hicks, Tomas Kron, David L. Ball
Journal: Journal of Thoracic Oncology (2015)
The Quest of the Holy Prepuce
Authors: W. R. Chynoweth
Journal: Annals of Internal Medicine (1927)

Article1 September 1927The Quest of the Holy PrepuceW. R. CHYNOWETH, M.D.W. R. CHYNOWETH, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-3-179 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEver since the unfortunate escape of all manner of diseases from the mythical box of Pandora, men have, through one means or other, attempted their cure. Whether through the savage incantations of voodooism, or through the various noxious potions used in the middle ages, or through knocking the devil literally and figuratively out of the patients as done by some tribes and even by the Puritans, or by means of the various cure-alls, manipulations, psychotherapy, ecclesiastical and otherwise, or through the spectro-chromotherapy of Ghaduli, or the magic hocus-pocus oscilloclastic box of Abrams, not forgetting the medicated gum drops, chewing gum... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Battle Creek, Michigan*From the Department of Urology, Battle Creek Sanitarium, Battle Creek, Michigan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1927Volume 1, Issue 3Page: 179-184KeywordsUrology ePublished: 1 December 2008 Issue Published: 1 September 1927 PDF downloadLoading ...
Abstract 5493: Genetic or Acquired CYP2C19 Enzyme Deficit is Associated With an Excess of Cardiovascular Risk in Clopidogrel-treated Patients
Authors: Jean-sebastien Hulot, Jean-Philippe Collet, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Olivier Barthélémy, Ghalia Anzaha, Farzin Beygui, Gilles Montalescot
Journal: Circulation (2009)

Introduction: Metabolic activation by CYP2C19 has emerged as a crucial determinant of clopidogrel responsiveness and efficacy. An increased risk of cardio-vascular events has been associated with the CYP2C19*2 allele, which causes loss-of-function, and with the use of proton pump inhibitors (PPI), which may also inhibit the CYP2C19, in clopidogrel-treated patients. We performed a meta-analysis to further estimate the relative effect in both sub-groups. Methods: Sixteen published or presented studies evaluating the association between the loss-of-function CYP2C19*2 genetic variant (8 studies, 9427 patients) or the use of PPI (8 studies, 35108 patients) and outcomes in patients treated with clopidogrel were included. Data on the occurrence of ischemic events (death, recurrent myocardial infarction, urgent revascularization) were extracted and combined using a fixed-effect model. Results: Of the 9427 patients, carriers of the loss-of-function CYP2C19*2 allele (28%, n=2674) displayed a 30% increase in the risk in any ischemic events compared to non carriers (10.4% vs 8.3%) (OR, 1.31; 95% CI, 1.12–1.53; p&lt;0.001). This single gene variant (CYP2C19*2) was also associated with an excess of cardiovascular mortality (1.8% vs 1.0%)(OR 1.79; 95% CI: 1.10–2.91, p&lt;0.019)(n=6225). PPI users (43%, n=15197) displayed an increased risk of ischemic events compared to non users (25.5% vs 19.4%) (OR, 1.48; 95% CI, 1.40–1.57; p&lt;0.001)(n=34496). This metanalysis also showed an excess of mortality (16.9% vs 11.5%)(OR 1.20; 95% CI: 1.08–1.33, p&lt;0.001)(n=15157) in PPI users compared to non users. When combining all data, CYP2C19 alteration due to the deficient allele or drug interaction has a 50% increased risk of ischemic events occurrence in clopidogrel treated patients (OR 1.49; 95% CI: 1.42–1.57, p&lt;0.001). Conclusions: CYP2C19*2 carriers and/or PPI users are patients exposed to a significantly increased risk of cardiovascular events when they are treated with clopidogrel.
ASSESSMENT OF RADIATION HAZARDS
Authors: W.M. Court Brown
Journal: BMJ (1961)

The minimum dose of radiation necessary to injure cells, induce tumors, and to shorten life is discussed. It is suggested that a given dose of radiation carries a risk of leukemia but that the risk is greater in old than young subjects. This was supported by chromosome counts. It was found that the number of hypomodal cells (with fewer chromosomes) and the number of hypermodal cells (with more chromosomes) increased with age. The number of these non-modal cells also increased after irradiation, particularly after whole-body irradiation or exposure of large areas. The relative number of abnormalities increased with the dose. The example is cited of 80 chromosomes in one leukocyte after irradiation of a patient for carcinoma of the testis. (H.H.D.)
Lesson of the Week: Fatal methadone overdose
Authors: T J Hendra, S P Gerrish, A R W Forrest
Journal: BMJ (1996)

Methadone is a synthetic opioid with potent analgesic effects often used for the detoxification or maintenance of an opiate addict. It differs from morphine in that it has an exceptionally prolonged duration of action with a half life averaging 25 hours, although durations of up to 52 hours have been reported during long term maintenance treatment.1 The variation in metabolism may be responsible for the irregular and unpredictable clinical course of patients who have taken overdoses of this agent.

Methadone overdose can follow an unpredictable course in non- tolerant patients, who are at risk of sudden death

A 22 year old man presented to the accident and emergency department at 1400 hours having taken an overdose of 420 mg of methadone three hours earlier; he had obtained the drug illicitly. He was a known drug misuser who had epilepsy, treated with sodium valproate. He had been treated before for depression with amitriptyline and fluoxetine. A heavy cigarette smoker with a high alcohol intake, he had taken four overdoses within the past two months.

On arrival he was drowsy and refused to submit to regular nursing observations. On leaving the hospital, he collapsed on the pavement while smoking a cigarette. After being brought back into the department, unconscious and unresponsive to pain, he was given three 0.4 mg boluses of intravenous naloxone and 0.4 mg flumazenil, with a prompt improvement in his level of consciousness. He was transferred to the admissions ward, where he cooperated poorly with monitoring by the nursing staff and hindered the use of a pulse oximeter by frequently getting out of bed and wandering out of the …
Role of Ki67 expression on survival of patients with lung cancer: a systematic review of the literature with meta-analysis
Authors: Céline Mascaux, Benoît Martin, Marianne Paesmans, Thierry Berghmans, Philippe Lothaire, Anne-Pascale Meert, Jean-Jacques Lafitte, Jean-Paul Sculier
Journal: Cancer Research (2004)

4734  Introduction: New biological parameters could become useful prognostic factors for cancer and particularly, for lung carcinoma. Among them, the Ki-67 gene codes for a DNA-binding nuclear protein which probably regulates cell proliferation. Ki-67 protein is expressed during each phase of the cell cycle except in G0 phase. Several studies have suggested that Ki-67 is associated with poor prognosis in lung cancer. We performed a systematic review of the literature to assess the prognostic value of Ki-67 overexpression for survival in patients with lung cancer. Methods: In order to aggregate the survival results, published studies on lung cancer assessing the prognostic value of Ki-67 for survival were identified by an electronic search in Medline. After performing for each individual trial a methodological assessment (according to a scale designed by the European Lung Cancer Working Party), we estimated the hazard ratio (HR) summarising the impact on survival of Ki-67 expression. A combined hazard ratio was obtained using both fixed-effect and random-effect models. Results: Forty-two studies were found to be eligible (5 were excluded because identical cohorts of patients were used), including 3983 patients. Forty-nine percent of the patients were considered as positive for the expression of Ki-67 according to the authors cut-off. Twenty-nine of the trials dealt with non small cell lung carcinoma (NSCLC), 1 with small cell carcinoma (SCLC), 2 with carcinoid tumours and 5 with any histology. In term of survival results according to Ki-67 expression, 15 studies were «negative» (significant detrimental effect) and 22 were not significant. The quality scores were statistically different between evaluable and non evaluable studies for meta-analysis (p = 0.002) but not between the significant and non-significant trials evaluable for the meta-analysis, allowing us to aggregate them. The SCLC and carcinoid tumours studies were not included in the meta-analysis. There was no detectable heterogeneity between studies (p = 0.12), but the power of this test is borderline. The combined HR for NSCLC, as calculated using a random-effects model, was 1.56 (95% CI: 1.30-1.87), showing a worse survival for NSCLC with Ki-67 expression. Conclusions: The expression of Ki-67 could be an univariate factor of poor prognosis for survival in NSCLC.